HighTower Advisors
OACC

HighTower Advisors’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

HighTower Advisors’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.4M Sell
510,836
-116,193
-19% -$1.24M 0.01% 1163
2025
Q4 		$6.63M Sell
627,029
-30,599
-5% -$324K 0.01% 1039
2025
Q3 		$6.91M Sell
657,628
-29,065
-4% -$304K 0.01% 1007
2025
Q2 		$7.18M Buy
686,693
+549,704
+401% +$5.7M 0.01% 941
2025
Q1 		$1.4M Buy
+136,989
New +$1.37M ﹤0.01% 1740

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

HighTower Advisors's OACC Position: Q1 2026 in Review

HighTower Advisors reduced its Oaktree Acquisition Corp III Life Sciences (OACC) stake by 19% in Q1 2026, selling an estimated $1.24M and leaving 510,836 shares worth $5.4M. The position accounts for 0.01% of the portfolio, ranked #1163.

HighTower Advisors first reported a position in OACC in Q1 2025 and has held it in 5 quarters since. The position peaked at $7.18M in Q2 2025. 51 funds tracked by Wall St. Rank hold OACC as of Q1 2026.

  • HighTower Advisors held 510,836 shares of Oaktree Acquisition Corp III Life Sciences worth $5.4M as of Q1 2026.
  • HighTower Advisors sold 116,193 Oaktree Acquisition Corp III Life Sciences shares in Q1 2026, an estimated $1.24M.
  • Oaktree Acquisition Corp III Life Sciences made up 0.01% of HighTower Advisors's portfolio in Q1 2026, its #1163 holding.
  • HighTower Advisors first reported a position in Oaktree Acquisition Corp III Life Sciences in Q1 2025 and has held it in 5 quarters since.
  • HighTower Advisors's Oaktree Acquisition Corp III Life Sciences position peaked at $7.18M in Q2 2025.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.